Evidence map›Paper›PMID 41634827›Full record

ArticleTrials2026

Effect of HIgh-Flow Therapy in Long-Term Oxygen Therapy (HILOT): study protocol for a multicentre, registry-based, randomised clinical trial.

Josefin Sundh, Mirjam Ljunggren, Andreas Palm, Eva Lindberg, Florent Lavergne, Ulla Møller Weinreich, Zainab Ahmadi, Magnus Ekström, HILOT Collaboration Group

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06247397 (Effect of HIgh-flow Therapy in Long-term Oxygen Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06247397 narecruitingnot on this map

Effect of HIgh-flow Therapy in Long-term Oxygen Therapy (HILOT): A Multicenter, Registry-based, Randomized Clinical Trial

TypeinterventionalSponsorSkane University HospitalRan2024 to 2028Enrolled310ConditionsChronic Obstructive Pulmonary Disease Severe, Interstitial Lung Disease, Chronic Respiratory Failure With HypoxiaArmsAdded high-flow oxygen therapy, Standard care
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Josefin SundhDepartment of Respiratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. josefin.sundh@oru.se.ORCID http://orcid.org/0000-0003-1926-8464
Mirjam LjunggrenDepartment of Medical Science, Respiratory-, Allergy- and Sleep Research, Uppsala University, Uppsala, Sweden.
Andreas PalmDepartment of Medical Science, Respiratory-, Allergy- and Sleep Research, Uppsala University, Uppsala, Sweden.
Eva LindbergDepartment of Medical Science, Respiratory-, Allergy- and Sleep Research, Uppsala University, Uppsala, Sweden.
Florent LavergneUniversité Pierre et Marie Curie, Paris, France.
Ulla Møller WeinreichDepartment of Respiratory Diseases, Aalborg University Hospital, Respiratory Research Aalborg, Aalborg University, Aalborg, Denmark.
Zainab AhmadiDepartment of Respiratory Medicine, Allergology and Palliative Medicine, Institution for Clinical Sciences in Lund, Lund University, Lund, Sweden.
Magnus EkströmDepartment of Respiratory Medicine, Allergology and Palliative Medicine, Institution for Clinical Sciences in Lund, Lund University, Lund, Sweden.
HILOT Collaboration Group

Funding

Svenska Läkaresällskapet SLS-985470Vetenskapsrådet 2019-02081
6 · The paper itself

Abstract

backgroundThe use of high-flow oxygen therapy (HFOT) compared with standard low-flow oxygen therapy (LFOT) may improve outcomes in people with oxygen-dependent chronic respiratory failure (CRF). The primary aim of this multicentre trial was to evaluate HFOT in addition to LFOT, compared with regular LFOT in people with CRF due to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

methodsRegistry-based randomised controlled trial (R-RCT) of people on LFOT for CRF due to COPD (n = 270) and ILD (n = 40), at ten Swedish secondary care centres within the Swedish Register for Respiratory Failure (Swedevox). People with ongoing LFOT are randomised in a 1:1 ratio to standard treatment with LFOT (control) or LFOT with added HFOT during nighttime and at the patient's discretion daytime (intervention). HFOT is provided using the ResMed Lumis HFT system and the AcuCare HFNC Cannula. Primary outcome is time to first hospitalisation or death up to 1 year in people with COPD. Secondary outcomes include symptoms, health-related outcomes (HRQL), health-economics, adverse events, and to explore the effects of HFOT in people with CRF due to ILD. Outcome data will be obtained from national registries and from patient questionnaires at 3 and 12 months. DISCUSSION: This R-RCT will combine the advantages of a prospective randomised trial and large clinical national registries to improve the evidence-based use of long-term oxygen therapy. Recruitment started in June 2024 and is ongoing.

trial registrationClinicalTrials.gov, ID: NCT06247397. Registered 2024-02-07.

Indexed as

LungLung Diseases, InterstitialOxygen Inhalation TherapyPulmonary Disease, Chronic ObstructiveRespiratory InsufficiencyHumansMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicRegistriesSwedenTime FactorsTreatment OutcomeAdverse eventsChronic obstructive pulmonary diseaseExacerbationsHigh-flow oxygen therapyHospitalisationsInterstitial lung diseaseLong-term oxygen therapyLow-flow oxygen therapyMortalitySymptoms

Identifiers

PMID41634827
PMCPMC12930620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.